Han Xu, MD/PhD/FAPCR
Medicine Invention Design Incorporation - IRB00009424 · Medicine Invention Design, Inc. - IRB00009424 - IORG0007849 · Medicine Invention Design Incorporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Han Xu, MD/PhD/FAPCR as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:46 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT07182838 · Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic MixHan Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair · active not recruiting · HIV Infections · study chair
- Ph2/Ph3NCT07145333 · Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair · active not recruiting · SCLC · study chair
- Early Ph1NCT06959563 · Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPVHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · active not recruiting · HPV Infection · study director
- Ph2/Ph3NCT06062810 · Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · active not recruiting · Breast Cancer · study chair
- Ph2/Ph3NCT05987956 · Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsMedicine Invention Design, Inc · active not recruiting · ALK-Positive Non-Small Cell Lung Cancer (NSCLC) · principal investigator
- Ph2/Ph3NCT03348670 · Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · active not recruiting · Prostate Cancer · study chair
- Early Ph1NCT03305341 · Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic MixHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · active not recruiting · Covid19 · study chair
- Ph1NCT02403505 · Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal CancerHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · active not recruiting · Rectal Cancer · study chair
- Ph2/Ph3NCT01064466 · Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair · active not recruiting · Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.